Will the FDA approve baxdrostat for hard-to-control hypertension?

Prediction market on kalshi. If the FDA approves baxdrostat for hard-to-control hypertension for marketing before Sep 1, 2026, then the market resolves to Yes.

24h Volume: $267.06. Liquidity: $267.06. Resolves: 9/8/2026.